New Parkinson's drug shows promise in early safety check
NCT ID NCT04291859
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 22 times
Summary
This early-stage study tested a new drug called Lu AF28996 in 57 people with Parkinson's disease. The main goal was to see if the drug is safe and how the body processes it. Researchers measured side effects and drug levels in the blood. This is a first step to see if the drug might help control symptoms in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta Center for Medical Research
Atlanta, Georgia, 30331, United States
-
Caen Normandy University
Caen, Basse-Normandie, 14033, France
-
CenExel Los Alamitos
Los Alamitos, California, 90720, United States
-
Curiositas-ad-sanum
Hamburg, 83527, Germany
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Hawaii Pacific Neuroscience
Honolulu, Hawaii, 96817, United States
-
Hosp. General Catalunya
Mira-Sol, 08195, Spain
-
Hospital Vall d´Hebron
Barcelona, 08035, Spain
-
Inland Nortwest Research
Spokane, Washington, 99202, United States
-
Neurology Consultants of Nebraska
Omaha, Nebraska, 68154, United States
-
Parkinson's Disease Treatment Center of SW FL
Port Charlotte, Florida, 33980, United States
-
QPS Netherlands BV
Leeuwarden, 8934 AD, Netherlands
-
QUEST Research Institute
Farmington Hills, Michigan, 48334, United States
-
Velocity
Hallandale, Florida, 33009, United States
-
Virgen Del Roccio
Seville, 41013, Spain
Conditions
Explore the condition pages connected to this study.